Mitra Biotech to focus on NextGen Cancer Immunotherapies
Mitra Biotech has recently announced a collaborative research partnership with Brigham and Women’s Hospital and the Department of Neurosurgery to further transform personalized immuno-oncology drug development. The agreement, with Dr Sean Lawler, Assistant Professor of Medicine and Managing Director of the
Harvey Cushing Neuro-oncology Laboratories at the Brigham, is to evaluate oncolytic viruses that have been developed in the Department of Neurosurgery at the hospital. These novel engineered versions of the Herpes Simplex Virus 1 (HSV1), which have been extensively characterized pre-clinically, are capable of selective infection and replication within tumor cells, and can stimulate the immune system. Clinical trials are now underway at the Brigham to investigate oncolytic viruses in patients with the aggressive and incurable brain tumor glioblastoma multiforme (GBM).